Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.
HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON) for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
December 18, 2019
RegMed Investors’ (RMi) closing bell: the sector is counterintuitive as today’s NASDAQ index inclined as my covered composite of companies declined
December 17, 2019
RegMed Investors’ (RMi) closing bell: sector breaks down as profiteering circles the upside
December 16, 2019
RegMed Investors’ (RMi) closing bell: the oversold’s ground moved upward
December 15, 2019
RegMed Investors’ (RMi) closing bell: buying the rumors, selling speculation as the sector gets slammed
December 11, 2019
RegMed Investors’ (RMi) closing bell: review the alternating December Advance/Decline lines
December 10, 2019
RegMed Investors’ (RMi) closing bell: acquisition speculation
December 10, 2019
RegMed Investors’ (RMi) pre-open: Futures are lower after a sector collapse
December 9, 2019
RegMed Investors’ (RMi) closing bell: selling pressures
December 6, 2019
RegMed Investors’ (RMi) pre-open: Friday’s theme is conjecture as futures fluctuate
35 companies, 1 interpreter!
Insight, foresight and recommendation
Histogenics (HSGX) -- Opened 2018 at $2.07, saw some ups at $2.92; opened February at $2.79 falling with a low of $2.50 to close 2/18 at $2.63.HSGX closed (1/25) its registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions with a solid book-running manager Canaccord Genuity. Another favorite ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors